Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iressa Activity Not Likely Predicted By EGFR Expression Level – AstraZeneca

Executive Summary

The level of EGFR expression seen in solid tumors is not a likely predictor of clinical activity observed with Iressa, AstraZeneca Iressa Global Product Director Linda Summerton said Nov. 7
Advertisement

Related Content

OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement
OSI Developing Tarceva I.V. Formulation, Expected To Aid In Reimbursement
AstraZeneca Prices Iressa At 25% Discount To Gleevec; Launch In May
AstraZeneca Prices Iressa At 25% Discount To Gleevec; Launch In May
AstraZeneca Casodex FDA Cmte. To Focus On Efficacy Differences In Trials
AstraZeneca Iressa NDA Review Complicated By Pneumonia Reports
Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary
Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary
AstraZeneca Iressa NDA Filing Complete: Will HIV Model Fly In Oncology?
Advertisement
UsernamePublicRestriction

Register

PS040766

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel